NIDDK Names New Scientific Director, Translational Research Director
|Dr. James Balow
||Dr. Michael W. Krause
Dr. Michael W. Krause was recently announced as
NIDDK’s new scientific director. He has been acting
deputy scientific director since August 2011, chief
of the Laboratory of Molecular Biology since 2006
and director of NIDDK’s Genomics Core Facility
He came to NIDDK in 1993 after a postdoctoral
fellowship with Dr. Harold Weintraub, an international
leader in molecular biology at the Fred
Hutchinson Cancer Research Center in Seattle.
There, Krause studied developmental gene regulation
in C. elegans, uncovering mRNA trans-splicing
and MyoD, a master regulator of muscle cell
development. He received a bachelor’s degree in
biology and doctorate in molecular, cellular and
developmental biology from the University of Colorado,
“I am looking forward to the challenges and opportunities
of the road ahead, and the chance to refocus
on the core elements that define a strong and
effective institute: great science and great people,
synergizing to advance discovery that improves
human health,” Krause said.
Known internationally for pioneering research on
the transcriptional regulation of cell fate determination
in C. elegans, Krause has focused much of his
career on muscle cell development. He has also collaborated
to study sensors of nutritional flux as they
relate to insulin and other signaling pathways, while
also exploring novel links to transcriptional regulation.
Other studies of cell cycle regulation, RNA
modification, neuronal signaling and heme uptake
using genetics, cell biology and whole-genome
approaches reflect Krause’s broad scientific interests.
“Mike brings to the position a strong commitment to science and teamwork,
broad leadership experience and a solid ability to listen, negotiate and make
tough decisions,” said NIDDK director Dr. Griffin Rodgers.
NIDDK clinical director Dr. James Balow concurred. “Mike Krause is already an
impressively effective spokesman for science and scientific excellence in the intramural
program. He has an uncanny talent for translating arcane science into
understandable concepts that can ignite the interest of a diverse constituency.
What better starting point for the scientific leader of a broad-based institute such
as NIDDK?” he said. “Add to this Mike’s natural problem-solving skills, decisiveness,
fair-mindedness, appreciation of the value of diverse approaches to science
and generosity of spirit, all [of which] lead me to predict that he will be an exceptionally
effective leader and manager of science for NIDDK and for NIH.”
Balow, who had also served as acting scientific director since August 2011,
will also take on a new role, with the additional title of director, translational
research, and the responsibility to strengthen such programs in the division. He
will encourage the transformation of basic scientific discoveries and pre-clinical
observations into appropriate clinical investigations, foster multidisciplinary
and interdisciplinary team science and accelerate the movement of promising
discoveries and technologies into public-private partnerships.
CSR Alumnus Behar Mourned
Dr. Marjam Behar, who had a 21-year career (1980-
2001) at the Center for Scientific Review and the Division
of Research Grants, died on July 2. She resided
in Lafayette Hill, Pa.
She retired as a scientific review administrator of a
study section in CSR’s biophysical and chemical sciences
integrated review group.
Behar was well-known at NIH for recruiting and
retaining top-notch reviewers and she excelled at
assembling the best talent and brightest minds to
review grant proposals for funding. In 2000, she received a CSR Director’s Award
“for her superb ability to recruit the ablest reviewers to her committees, for
her dedication to successfully dealing with heavy review workloads, and for her
unceasing promotion of the scientific review process.”
In addition, in 1997 she was honored with the naming of a symposium in her
honor, on advances in bioanalytical and bioinorganic chemistry, at the 213th
meeting of the American Chemical Society in San Francisco.
She also found time to be a mentor for the American Chemical Society’s Project
SEED (Summer Educational Experience for the Economically Disadvantaged),
and while at NIH, she served as chair of the local SEED chapter. In recognition of
her commitment to the project, she was awarded an NIH EEO Special Achievement
Award in 1997.
She is survived by her husband, Joseph, her children, Robert, Jamie and Saul
and by four grandchildren.
In lieu of flowers, donations can be made in memory of Marjam G. Behar to the
American Chemical Society: Project SEED and mailed to American Chemical
Society, Development Office, 1155 16th Street, NW, Washington, DC 20036. The
direct link to donate online is www.donate.acs.org/program/seed.
NINR Council Welcomes Five New Members
NINR director Dr. Patricia Grady (front, c) welcomes new council members Dr. Anne Rosenfeld (front, l), Dr. Julie Anderson; (rear, from l) Col. Bruce Schoneboom, Dr. Susan Gennaro and Dr. William Holzemer.
Photo: Bill Branson
NINR director Dr. Patricia Grady recently welcomed five new members to the National Advisory Council for Nursing Research, the principal advisory board for NINR.
Dr. Julie Anderson is an associate professor of nursing at the University of North Dakota. She has extensive experience in neonatal intensive care nursing and her primary research interests center around skin and wound care.
Dr. Susan Gennaro is dean and professor of Connell School of Nursing at Boston College. Her research focuses on the improvement of global perinatal health and the identification of causes of preterm birth in minority women in the U.S.
Dr. William L. Holzemer is professor and dean at Rutgers University College of Nursing. His research examines quality of nursing education, quality of nursing care, outcomes research, variation in practice, self-care symptom management and quality of life, with special emphasis on people living with and affected by HIV infection.
Dr. Anne Rosenfeld is professor and associate dean for research at the University of Arizona College of Nursing. Her research focuses on symptom management for women with acute coronary syndrome.
Col. Bruce A. Schoneboom is the incoming commander for the Army Medical Research Institute for Chemical Defense at Aberdeen Proving Grounds, Md. His research interests include investigating neuro-immune responses of the central nervous system to viral pathogens with known bioterrorist capabilities and the development of new monitoring technologies with operational and garrison applications.